Acute Myeloid Leukaemia:KOL Insight [Report Updated: 01022018] Prices from USD $8495
How will four newly approved therapies transform treatment of AML?
For decades, there were no approved treatments for acute myeloid leukaemia AML other than chemotherapies. The past year has witnessed the approval of four new therapies for AML; Novartis' Rydapt, Celgene/Agios' Idhifa, Jazz Pharma's Vyxeos and Pfizer's Mylotarg. How are these agents faring on the market so far and will more personalised treatments follow their lead? AbbVie/Roche's Venclexta/Venclyxto venetoclax, Astellas' gilteritinib and Agios' ivosidenib all form part of a rich pipeline, but which drugs stand out to key opinion leaders KOLs?
Learn how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Acute Myeloid Leukaemia. Twelve US and European KOLs give their insight on six marketed products and 13 pipeline programmes. KOLs also provide their candid views on the potential for novel chemotherapies and earlystage pipeline programmes.
Take a tour of the report now
The table of contents >
The key business questions answered >
The key KOL quotes >
See the therapies covered >
Find out who the 6 EU 6 US KOLs are >
Review an extract from the report 1 drug profile >
Chemotherapies dominated the landscape for 40 years, but how has this all changed in the last year? Four therapies have been approved for AML in the past year [Novartis' Rydapt, Celgene/Agios' Idhifa, Jazz Pharma's Vyxeos and Pfizer's Mylotarg]. Find out how KOLs perceive these agents and how the landscape will continue to evolve.
Three nextgeneration FLT3 inhibitors are in the pipeline but how can they successfully differentiate themselves? Novartis' Rydapt is currently in the lead with nextgeneration FLT3 agents hot on its heels. Find out how KOLs weigh up these nextgeneration drugs against Rydapt.
How do KOLs perceive the IDH inhibitors Idhifa and ivosidenib? How do the experts view the response rates obtained with this class of molecularlytargeted agents andwhere do they envisage these niche agents fitting in longterm?
Which of the pipeline drugs hold the most promise in AML? KOLs weigh up the data so far with AbbVie/Roche's Venclexta/Venclyxto venetoclax, Helsinn/MEI Pharma's pracinostat and Roche's idasanutlin and reveal which drug they view as most promising in AML.
Will novel chemotherapies have a chance to improve upon older agents and if so, what challenges do they face? Novel chemotherapies such as Otsuka/Astex' guadecitabine are hoping to compete with conventional standardofcare regimens. Find out what KOLs think about this.
What other earlystage programmes are KOLs particularly excited about? The earlystage pipeline for AML encompasses PD1 inhibitors, CART therapies and other bispecific monoclonal antibody approaches. Which ones do KOLs hold high hopes for?
More personalised approaches on the horizon for AML? Do KOLs believe AML has reached a key turning point where toxic chemotherapy regimens will be replaced by targeted drugs?
It's going in the right direction. AML is being unfolded as multiple diseases which are defined by single mutations. It's getting more into the targeted therapies. Standard chemotherapy will probably disappear from the scene in a decade. EU Key Opinion Leader
The FLT3 inhibitors [are the most promising]. If I had to put another one, I would put venetoclax.US Key Opinion Leader
Sample of therapies covered
Rydapt midostaurin; Novartis
Vyxeos CPX351; Jazz Pharmaceuticals
Mylotarg gemtuzumab ozogamicin; Pfizer
Dacogen decitabine; Otsuka/Janssen
Vidaza azacitidine; Celgene
quizartinib Daiichi Sankyo
crenolanib Arog Pharmaceuticals
ivosidenib Agios Pharmaceuticals
Venclexta/Venclyxto venetoclax; AbbVie/Roche
pracinostat Helsinn/MEI Pharma
Opdivo nivolumab; BristolMyers Squibb
IomabB Actinium Pharmaceuticals
adastuximab talirine Seattle Genetics
guadecitabine Otsuka/Astex Pharmaceuticals
KOLs from North America
Dr. Mark Levis, MD PhD, Associate Professor of Oncology and Medicine in the Division of Hematologic Malignancies at the John Hopkins School of Medicine, Maryland, Baltimore
Dr. Farhad Ravandi MD, Professor and Chief in the Department of Leukemia at MD Anderson, Houston, Texas
Dr. Roland B. Walter MD PhD MS, Associate Professor of Medicine, Division of Hematology, University of Washington School of Medicine, Seattle.Dr Farhad Ravandi, MD, Professor and Chief in the Department of Leukaemia at MD Anderson, Houston, Texas
Dr. Daniel Pollyea MD MS, Assistant Professor of Medicine and Clinical Director of Leukemia Services in the Division of Hematology, School of Medicine at the University of Colorado, Colorado
Dr. James K. Mangan MD PhD, Assistant Professor of Clinical Medicine at the Abramson Cancer Center, Perelman Center for Advanced Medicine, University of Pennsylvania Penn Medicine, Philadelphia, Pennsylvania
Dr. Ran Reshef MD, Director of Translational Research, Blood and Marrow Transplantation in the Division of Hematology/Oncology at the Columbia University Medical Center, New York
KOLs from Europe
Professor Bruno Quesnel MD PhD, Professor of Hematology at the University of Lille and Hospital ClaudeHuriez CHRU Lille, France
Dr. Donal McLornan MB BCH Honours PhD MRCP FRCPath, Consultant Haematologist at King's College Hospital London, London, UK
Dr. Richard Dillon MBBS PhD MRCP FRCPath, Consultant Haematologist at Guy's and St Thomas' Hospitals, London, UK
Dr. Nicolas Blin MD, Consultant Physician of Hematology at Nantes University Hospital, France
Anonymous German KOL MD PhD, Professor of Haematology and Oncology at a leading University Hospital, Germany
Anonymous German KOL MD PhD, Professor at the Department of Haematology and Oncology at a leading University Hospital, Germany
Money Back Guarantee!
At FirstWord, we stand behind our reports. If you're not completely satisfied, we'll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering uptotheminute pharma news, insight, analysis and expert views of importance to your company's success.
FirstWord Reports deliver timely, needtoknow intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.
Learn more at www.firstwordgroup.com.
Original Article: Acute Myeloid Leukaemia:KOL Insight [Report Updated: 01022018] Prices from USD $8495
More From BioPortfolio on "Acute Myeloid Leukaemia:KOL Insight [Report Updated: 01022018] Prices from USD $8495"